Abstract
To investigate the usefulness of positron emission tomography (PET) in detecting I-131 nonvisualized metastatic foci of well-differentiated thyroid carcinoma (WDTC), 2 patients with papillary and follicular thyroid carcinoma respectively, were studied with I-131 total body scan, thallium-201 scan, Tc99m bone scan and [18F]-2-deoxy-2-fluoro-D-glucose (FDG) PET. Case 1 showed no metastatic lesion in I-131 (up to 150mCi) total body scan, 1 anterior mass in thallium-201 scan, none in Tc99m bone scan and 7 including the main anterior mediastinal mass in FDG-PET. Case 2 showed 2 metastatic lesions in I-131 (150mCi) total body scan, 11 bony metastatic lesions in Tc99m bone scan and 13 in FDG-PET. However, lower extremities were not scanned in FDG-PET. Tumor/background ratio of 1.5 or above is needed to be visualized grossly. The FDG-PET tumor/background ratios are higher than those of thallium-201 except in one site. In conclusion, I-131 scintigraphy is still the first line method to use in detecting WDTC recurrence and metastasis, as I-131 has the advantage of being both a therapeutic and imaging agent. For I-131 nonvisualized metastasis of WDTC, thallium scintigraphy and FDG-PET may be considered. Even though FDG-PET has better sensitivity, resolution imaging and spatial localization, this has to be balanced with its higher cost when compared with thallium scintigraphy.
Similar content being viewed by others
References
Mazzaferri E.L. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am. J. Med. 97: 418, 1994.
Schlumberger M., Mancusi F., Baudin E., Pacini F. 131 I therapy for elevated thyroglobulin levels. Thyroid 7: 273, 1997.
Wahl R.L., Harney J., Hutchins G.D., Grossman H.B. Imaging of renal cancer using positron emission tomography with 2-deoxy-2- (18F)-fluoro-D-glucose: pilot animal and human studies. J. Urol. 146: 1470, 1991.
Wahl R.L., Cody R.L., Hutchins G.I., Mudgett E.E. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 179: 765, 1991.
Ichiya Y., Kuwabara Y., Otsuka M., Tahara T., Yoshikai T., Fukumura T., Jingu K., Masuda K. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J. Nucl. Med. 32: 1655, 1991.
Dadparvar S., Krishna L., Brady L.W., Slizofski W.J., Brown S.J., Chevres A., Micaily B. The role of iodine-131 and thallium-201 imaging and serum thyroglobulin in the management of differentiated thyroid carcinoma. Cancer 71: 3767, 1993.
Meier C.A., Braverman L.E., Ebner S.A., Veronikis I., Daniels G.H., Ross D.S., Deraska D.J., Davies T.F., Valentine M., De Groot L.J., Curran P., McEllin K., Reynolds J., Robbins J., Weintraub B.D. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J. Clin. Endocrinol. Metab. 78: 188, 1994.
Ashcraft M.A., Van Herle A.J. The comparative value of serum thyroglobulin measurements and iodine-131 total body scan in the follow-up study of patients with treated differentiated thyroid cancer. Am. J. Med. 71: 806, 1981.
Pacini F., Lippi F., Formica N., Elisei R., Anelli S., Ceccarelli C., Pinchera A. Therapeutic dose of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin. J. Nucl. Med. 28: 1888, 1987.
Sherman S.I., Tielens E.T., Sostre S., Wharam M.D. Jr, Ladenson P.W. Clinical utility of post-treatment radioiodine scans in the management of patients with thyroid carcinoma. J. Clin. Endocrinol. Metab. 78: 629, 1994.
Pineda J., Lee T., Ain K.J., Reynolds J., Robbin J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scans. J. Clin. Endocrinol. Metab. 80: 1488, 1995.
Pachucki J., Burmeister L.A. Evaluation and treatment of persistent thyroglobulinemia in patients with well-differentiated thyroid cancer. Eur. J. Endocrinol. 137: 254, 1997.
Hisada K., Tonami N., Miyamae T., Hiraki Y., Yamazaki T., Maeda T., Nakajo M. Clinical evaluation of tumor imaging with TI-201 chloride. Radiology 129: 497, 1978.
Brendel A.J., Guyot M., Jeandot R., Lefort G., Manciet G. Thallium-20 1 imaging in the follow-up of differentiated thyroid carcinoma. J. Nucl. Med. 29: 1515, 1988.
Bessell E.M., Foster A.B., Westwood J.H. The use of deoxyfluoro-D-glucopyranoses and related compounds in a study of yeast hexokinase specificity. Biochem. J. 128: 199, 1972.
Bessell E.M., Thomas P. The effect of substitution at C-2 of D-glucose 6-phosphate on the rate of dehydrogenation by glucose 6-phosphate dehydrogenase (from yeast and from rat liver). Biochem. J. 131: 83, 1973.
Gallagher B.M., Fowler J.S., Gutterson N.I., Mac-Gregor R.R., Wan C.N., Wolf A.P. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F] 2-deoxy-2 fluoro-D-glucose. J. Nucl. Med. 19: 1154, 1978.
Dichiro G. Positron emission tomography using 18-F-fluoro-deoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest. Radiol. 22: 360, 1987.
Joensuu H., Ahonen A., Klemi P.J. 18F-fluorodeoxyglucose imaging in preoperative diagnosis of thyroid malignancy. Eur. J. Nucl. Med. 13: 502, 1988.
Adler L.P., Bloom A.D. Positron emission tomogrophy of thyroid masses. Thyroid 3: 195, 1993.
Grunwald F., Schomburg A., Bender H., Klemm E., Menzel C., Bultmann T., Palmedo H., Ruhlmann J., Kozak B., Biersack H. Fluorine-18-fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur. J. Nucl. Med. 23: 312, 1996.
Feine U., Lietzenmayer R., Hanke J.P., Wohrle H., Muller-Schauemburg W. 18FDG whole-body PET in differentiated thyroid carcinoma, Flipflop in uptake patterns of 18FDG and 131I. Nucl. Med. 34: 127, 1995.
Feine U., Lietzen Mayer R., Hankie J., Wohrle H., Muller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J. Nucl. Med. 37: 1468, 1996.
Dietlein M., Scheidhauer K., Voth E., Theissen P., Schicha H. Fluorine-18-fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur. J. Nucl. Med. 24: 1342, 1997.
Gasparoni P., Rubello D., Ferlin G. Potential role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma. J. Endocrinol. Invest. 20: 527, 1997.
Bronnegard M., Torring O., Boos J., Sylven C., Marcus C., Wallin G. Expression of thyrotropin receptor and thyroid hormone receptor messenger ribonucleic acid in normal, hyperplastic and neoplastic human thyroid tissue. J. Clin. Endocrinol. Metab. 79: 384, 1992.
Robbins R., Ghossein R., Rosai J., Levy O., Carrasco N. Localization of immunoreactive Na+/I− symporter (ir-NIS) in normal and neoplastic thyroid cells. 79th Annual meeting of the Endocrine Society. Abstract P2-32 Minneapolis, Minnesota, U.S.A., June 11–14, 1997.
Sisson J.C., Ackermann R.J., Meyer M.A., Wahl R.L. Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implication for diagnosis and therapy. J. Clin. Endocrinol. Metab. 77: 1090, 1993.
Aktolun C., Bayhan H., Kir M. Clinical experience with Tc-99mMIBI imaging in patients with malignant tumors. Preliminary results and comparison with TI-201. Clin. Nucl. Med. 17: 171, 1992.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Huang, TS., Chieng, P.U., Chang, C.C. et al. Positron emission tomography for detecting iodine-131 nonvisualized metastasis of well-differentiated thyroid carcinoma: Two case reports. J Endocrinol Invest 21, 392–398 (1998). https://doi.org/10.1007/BF03350776
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03350776